Resource Logo
FDA News

Labeling changes for Kaletra reflecting new QT/QTC interval and PR interval prolongation information




 

Food and Drug Administration - April 6, 2009

Labeling changes for Kaletra reflecting new QT/QTC interval and PR interval prolongation information FDA approved, on April 6, 2009, changes to the product label for Kaletra (lopinavir/ritonavir) Tablets and Oral Solution, reflecting new WARNINGS and PRECAUTIONS regarding QT/QTC interval and PR interval prolongation information.



 


Copyright © 2009 -FDA News, Publisher. All rights reserved to Food and Drug (FDA) Administration FDA.

Information in this article was accurate in April 6, 2009. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.